search
Back to results

TiVi Evaluation of Microcirculatory Reactivity of the Skin to Galvanic Stimulation: Effect of Aspirin (PIRAAT)

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
TiVi system
Sponsored by
University Hospital, Angers
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • subjects referred for investigation of peripheral arterial disease.
  • Affiliation to the French National healthcare system
  • French speaking patients
  • Ability to stand still for half a minute.

Exclusion Criteria:

  • pregnancy
  • inability to understand the study goal
  • Patients protected by decision of law

Sites / Locations

  • UH Angers

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PAD patients

Arm Description

Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD). Intervention is measurement of microvascular response to current application on the skin by TiVi system

Outcomes

Primary Outcome Measures

Factor associated with CIV amplitude
Determination of the coefficient r² characterizing the quality of the univariate linear regression explaining the Delta2 (maximum differential amplitude of the response to galvanic current between stimulated and non-stimulated zone) by the quantity of aspirin administered (expressed in mg).

Secondary Outcome Measures

Role of aspirin in impaired CIV
Likelihood ratio comparison of the univariate model to a multivariate model including all factors, primarily medicated, that may be associated with impaired CIV in vascular patients
Determination of the CIV cut-off value to optimally discriminate patients on aspirin from patients not taking aspirin
Delta2 value (threshold CIV) minimizing distance to 100/100% sensitivity / specificity of receiver operating characteristics (ROC) analysis
Survival rate without major cardiovascular event (MACE) in patients with or without aspirin
the event-free survival rate is defined as the time between the inclusion date and the event date. If no event is observed at 24 months
Survival rate without major cardiovascular event (MACE)in patients with aspirin according to the CIV response.
the event-free survival rate is defined as the time between the inclusion date and the event date. If no event is observed at 24 months

Full Information

First Posted
November 20, 2017
Last Updated
June 23, 2022
Sponsor
University Hospital, Angers
search

1. Study Identification

Unique Protocol Identification Number
NCT03357367
Brief Title
TiVi Evaluation of Microcirculatory Reactivity of the Skin to Galvanic Stimulation: Effect of Aspirin
Acronym
PIRAAT
Official Title
Performance du TiVi Pour évaluer la réactivité Microcirculatoire de la Peau à l'Application d'un Courant Galvanique, Effet de l'Aspirine
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
February 8, 2018 (Actual)
Primary Completion Date
September 26, 2021 (Actual)
Study Completion Date
September 26, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Prospective interventional study. The aim is to analyze the effect of usual ongoing treatments over microvascular cutaneous response to galvanic current applications (CIV: current induced vasodilatation) with tissue vitality (TiVi) system on the forearm of subjects referred for ultrasound investigations due to suspicion of peripheral disease. Hypothesis is that the use of aspirin (even at low dose) abolishes the response. This test could make it possible to detect the functional effects of low dose aspirin without using biological tests. A routine clinical application could be to use this CIV to verify adherence to aspirin.
Detailed Description
At admission eligible patients are proposed to participate. Written consent is signed after complete oral and written explanation of the protocol is signed. No register of non-included patients will be kept. In included patients, in parallel to the routine ultrasound investigation for which the patient is referred, microvascular investigation will be performed as explained later in arm description. Usual ongoing treatments are obtained by history and recorded. The end of the visit is the end of the participation of the subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
830 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PAD patients
Arm Type
Experimental
Arm Description
Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD). Intervention is measurement of microvascular response to current application on the skin by TiVi system
Intervention Type
Device
Intervention Name(s)
TiVi system
Intervention Description
Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes. Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later. Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded
Primary Outcome Measure Information:
Title
Factor associated with CIV amplitude
Description
Determination of the coefficient r² characterizing the quality of the univariate linear regression explaining the Delta2 (maximum differential amplitude of the response to galvanic current between stimulated and non-stimulated zone) by the quantity of aspirin administered (expressed in mg).
Time Frame
10 minutes after the second period of current application
Secondary Outcome Measure Information:
Title
Role of aspirin in impaired CIV
Description
Likelihood ratio comparison of the univariate model to a multivariate model including all factors, primarily medicated, that may be associated with impaired CIV in vascular patients
Time Frame
10 minutes after the second period of current application
Title
Determination of the CIV cut-off value to optimally discriminate patients on aspirin from patients not taking aspirin
Description
Delta2 value (threshold CIV) minimizing distance to 100/100% sensitivity / specificity of receiver operating characteristics (ROC) analysis
Time Frame
10 minutes after the second period of current application
Title
Survival rate without major cardiovascular event (MACE) in patients with or without aspirin
Description
the event-free survival rate is defined as the time between the inclusion date and the event date. If no event is observed at 24 months
Time Frame
at 12 months and 24 months
Title
Survival rate without major cardiovascular event (MACE)in patients with aspirin according to the CIV response.
Description
the event-free survival rate is defined as the time between the inclusion date and the event date. If no event is observed at 24 months
Time Frame
at 12 months and 24 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: subjects referred for investigation of peripheral arterial disease. Affiliation to the French National healthcare system French speaking patients Ability to stand still for half a minute. Exclusion Criteria: pregnancy inability to understand the study goal Patients protected by decision of law
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samir MD HENNI, PhD
Organizational Affiliation
UH Angers
Official's Role
Principal Investigator
Facility Information:
Facility Name
UH Angers
City
Angers
ZIP/Postal Code
49100
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33161777
Citation
Ramondou P, Hersant J, Fouquet O, Sempore WY, Abraham P, Henni S. Current-Induced Vasodilation Specifically Detects, and Correlates With the Time Since, Last Aspirin Intake: An Interventional Study of 830 Patients. J Cardiovasc Pharmacol Ther. 2021 May;26(3):269-278. doi: 10.1177/1074248420971165. Epub 2020 Nov 7.
Results Reference
derived

Learn more about this trial

TiVi Evaluation of Microcirculatory Reactivity of the Skin to Galvanic Stimulation: Effect of Aspirin

We'll reach out to this number within 24 hrs